STOCK TITAN

Cardiff Oncology (CRDF) Stock News, Feb-May 2024

CRDF NASDAQ

Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.

Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology firm specializing in PLK1 inhibition to develop cancer therapies, will present at the Jefferies Healthcare Conference in New York on June 5-6, 2024. CEO Mark Erlander will present on June 5, 2024, from 8:30 to 8:55 AM ET in Track 8. The company will also hold 1x1 meetings with investors. Interested parties can access live webcasts and replays of the presentations via Cardiff Oncology's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at two investor conferences in May 2024. The first, H.C. Wainwright 2nd Annual BioConnect Investor Conference, will be held at the Nasdaq Headquarters in New York City on May 20, 2024, at 2:30 PM ET. The second, Cowen 5th Annual Oncology Innovation Summit, will be a virtual event on May 29, 2024, at 1:30 PM ET. CEO Mark Erlander will represent Cardiff Oncology in fireside chats at both events. Interested parties can access live webcasts via Cardiff Oncology's website, with replays available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
conferences
-
Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF) reported Q1 2024 results and provided a business update, highlighting strong efficacy in RAS-mutated mCRC and onvansertib's potential across various cancers. The company has $67M in cash, projecting runway into Q3 2025. Key milestones include upcoming data readouts, trials, and preclinical data presentations. Financially, total operating expenses decreased, with funds expected to last into Q3 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.43%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.87%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.40%
Tags
conferences

FAQ

What is the current stock price of Cardiff Oncology (CRDF)?

Cardiff Oncology (CRDF) last closed at $0.8390.

What is the market cap of Cardiff Oncology (CRDF)?

The market cap of Cardiff Oncology (CRDF) is approximately $65.3M.